Immunoglobulins binding human Vγ9Vδ2 T cell receptors

Abstract

The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated

1 - 26 . (canceled) 
     
     
         27 . A bispecific immunoglobulin molecule comprising an antibody that activates human Vγ9Vδ2 T cells linked to a target-specific antibody, wherein said antibody that activates human Vγ9Vδ2 T cells binds the Vδ2 chain of a Vγ9Vδ2 T cell receptor. 
     
     
         28 . The bispecific immunoglobulin molecule according to  claim 27 , wherein said target specific antibody is a tumor-antigen-specific antibody. 
     
     
         29 . The bispecific immunoglobulin molecule according to  claim 27 , wherein said antibody that activates human Vγ9Vδ2 T cells is a single chain or a single domain antibody. 
     
     
         30 . The bispecific immunoglobulin molecule according to  claim 27 , wherein said antibody that activates human Vγ9Vδ2 T cells is a single chain antibody and said target-specific antibody is a single chain antibody. 
     
     
         31 . The bispecific immunoglobulin molecule according to  claim 27 , wherein said antibody that activates human Vγ9Vδ2 T cells is a single domain antibody and said target-specific antibody is a single domain antibody. 
     
     
         32 . A bispecific immunoglobulin molecule comprising a VHH that activates human Vγ9Vδ2 T cells linked to a target-specific VHH, wherein said VHH that activates human Vγ9Vδ2 T cells binds the Vδ2 chain of a Vγ9Vδ2 T cell receptor. 
     
     
         33 . A bispecific immunoglobulin molecule comprising an antibody that activates human Vγ9Vδ2 T cells linked to a target-specific antibody, wherein said antibody that activates human Vγ9Vδ2 T cells binds Vγ9Vδ2 double-positive T cells and Vδ2 single-positive T cells, but not Vγ9 single-positive T cells. 
     
     
         34 . The bispecific immunoglobulin molecule according to  claim 28 , wherein said bispecific immunoglobulin molecule at a concentration of 10 nM is capable of inducing lysis of a higher percentage of A431 tumor cells during overnight incubation than reference bispecific immunoglobulin molecules which do not have both the antibody that activates human Vγ9Vδ2 T cells and the tumor-antigen-specific antibody. 
     
     
         35 . A method for the treatment of cancer comprising administration, to a subject in need thereof, of a bispecific immunoglobulin molecule comprising an antibody that activates human Vγ9Vδ2 T cells linked to a tumor-antigen specific antibody, wherein said antibody that activates human Vγ9Vδ2 T cells binds the Vδ2 chain of a Vγ9Vδ2 T cell receptor.